Business
J&J’s Stelara arthritis drug is unaffordable, Colorado price board rules (NYSE:JNJ)
Aamulya/iStock via Getty Images
- Johnson & Johnson’s (NYSE:JNJ) blockbuster arthritis drug may face a limit on what health plans in Colorado pay for the treatment after the state’s review board said it was “unaffordable” for patients, Bloomberg Law reported.
- The Colorado Prescription Drug Affordability Board on Friday voted to designate Stelara, an injectable treatment for conditions such as moderate to severe plaque psoriasis and Crohn’s disease, as too pricey.
- As a result of the vote, the five-member board in a follow-up meeting will decide whether to pursue an upper payment limit (UPL) for the drug. The board determined that Stelara on average cost $155,000 per Colorado patient in 2022, Bloomberg Law reported.
- The board will meet next on June 14.
More on Johnson & Johnson
Source link
